PraediCare Dx™

PraediCare Dx is a first-in-class Laboratory Diagnostic Test that is predictive of patients’ response to apoptosis-inducing therapies.

Conforming to regulatory standards, it is the only commercially available, CLIA-validated apoptosis phenotyping platform with functional readout for hematological malignancies.

In clinical use

It is currently in use in biomarker driven FDA accelerated clinical trial for a CDK9-inhibitor regimen in AML. Platform-based tests are also being implements in a range of clinical studies for combination therapies, both in blood cancer and solid cancer indications.

PraediCare™ DX (AML) Clinical Test

Our AML flow cytometry-based assay is designed for testing readily available peripheral blood or bone marrow biopsy samples, which are typically obtained during patient diagnosis. Individual tests for several treatment options have been developed and validated in our CLIA-certified laboratory. Results from clinical studies have been published in high impact, medical journals. Larger scale verification studies are underway with pharma and academic collaborators.

PraediCare™ DX (CLL) Clinical Test

For CLL patient samples, a fluorescent plate-based version of the assay is used for testing patient samples. Initial clinical studies have identified new predictive biomarker algorithms that predict patient response to those treatments and that forecast an onset of certain adverse events in those patients. Larger verification studies are underway with pharma and academic collaborators to support reimbursement.

For MM patient samples, a fluorescent plate-based version of the assay is used for testing patient samples. Some preliminary clinical studies have identified new predictive biomarker algorithms that predict patient response to treatments and that forecast overall survival in those patients. Larger verification studies are underway with pharma and academic collaborators to support reimbursement.